Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects With Alopecia Areata

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects With Alopecia Areata

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosnilimab (Primary)
  • Indications Alopecia areata
  • Focus Therapeutic Use
  • Acronyms AZURE
  • Sponsors AnaptysBio

    • Most Recent Events

    • 01 Dec 2022 According to an AnaptysBio media release, blinded interim review of alopecia areata Phase 2a data demonstrated rosnilimab proof of mechanism with robust reductions in peripheral PD-1 high and PD-1+ T cells and suggests administration was generally safe and well tolerated; However, absolute SALT scores were not supportive of the target product profile and further development in alopecia areata will not be pursued
    • 08 Aug 2022 According to an AnaptysBio media release, topline data from this trial anticipated in the Q1 2023.
    • 27 Apr 2022 According to an AnaptysBio media release, topline data from this trial anticipated in the first half of 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top